Melissa Girard, PA
Family · Blanchester, OHNPI 1801254966
Payments from drug & device makers
Across 153 payments — averaging $16.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$708
- Lilly USA, LLC$444
- Novo Nordisk$175
- AstraZeneca$166
- Exact Sciences$113
- Pfizer$104
- plus $800 from 19 others
What the payments were for
- Food & beverage$2,510100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 41 | $708 |
| Lilly USA, LLC | 33 | $444 |
| Novo Nordisk | 11 | $175 |
| AstraZeneca | 10 | $166 |
| Exact Sciences | 6 | $113 |
| Pfizer | 5 | $104 |
| GSK | 5 | $85 |
| Boehringer Ingelheim | 3 | $63 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $54 |
| Astellas Pharma US Inc | 3 | $52 |
| Johnson & Johnson | 4 | $52 |
| Dexcom, Inc. | 3 | $52 |
| Bayer | 3 | $51 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $48 |
| Biohaven Pharmaceuticals, Inc. | 2 | $48 |
| Novartis | 3 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| Esperion Therapeutics, Inc. | 2 | $36 |
| Abbott | 2 | $36 |
| Phathom Pharmaceuticals, Inc. | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Medtronic | 2 | $26 |
| Antares Pharma, Inc. | 1 | $25 |
| Amgen | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
How this compares
$2,510 in reported general payments places this provider in the 85th percentile of 6,812 family providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 60 | $90,181 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 96 | $68,420 |
| TrulicityDulaglutide | 47 | $54,588 |
| EliquisApixaban | 67 | $49,301 |
| JardianceEmpagliflozin | 40 | $47,486 |
| VraylarCariprazine Hcl | 16 | $33,824 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $23,216 |
| FarxigaDapagliflozin Propanediol | 17 | $22,552 |
| MounjaroTirzepatide | 20 | $20,577 |
| XareltoRivaroxaban | 12 | $17,946 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 68 | $11,921 |
| MyrbetriqMirabegron | 12 | $11,091 |
| SymbicortBudesonide/Formoterol Fumarate | 31 | $8,060 |
| JanuviaSitagliptin Phosphate | 12 | $6,764 |
| Novolog FlexpenInsulin Aspart | 22 | $6,047 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog Mix 70-30 | $175 | $92,34471 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $444 | $75,16567 claims |
| GSKTrelegy Ellipta | $85 | $68,42096 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $166 | $53,82779 claims |
| PfizerEliquis | $104 | $49,30167 claims |
| Boehringer IngelheimJardiance | $63 | $47,48640 claims |
| AbbVieVraylar, Synthroid | $708 | $35,14154 claims |
| Johnson & JohnsonXarelto | $52 | $17,94612 claims |
| Astellas Pharma US IncMyrbetriq | $52 | $11,09112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,812 family providers in Ohio.
Other family in Blanchester
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.